NCT02325674 MEASuRE: Metreleptin Effectiveness And Safety Registry
| NCT ID | NCT02325674 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Condition | Generalised Lipodystrophy |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2016-10-11 |
| Primary Completion | 2031-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2016-10-11 with a primary completion date of 2031-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.
Eligibility Criteria
Inclusion Criteria: * Patients treated with metreleptin through commercial supply at the time or before enrolment into registry * Patients who provide a written consent * Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply Exclusion Criteria: • Patients currently treated with an investigational agent as part of a clinical trial
Contact & Investigator
Lori Hartnett
STUDY DIRECTOR
Amryt Pharmaceuticals DAC
Frequently Asked Questions
Who can join the NCT02325674 clinical trial?
This trial is open to participants of all sexes, studying Generalised Lipodystrophy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02325674 currently recruiting?
Yes, NCT02325674 is actively recruiting participants. Contact the research team at clinicaltrials_info@chiesi.com for enrollment information.
Where is the NCT02325674 trial being conducted?
This trial is being conducted at Birmingham, United States, Duarte, United States, Atlanta, United States, Chicago, United States and 11 additional locations.
Who is sponsoring the NCT02325674 clinical trial?
NCT02325674 is sponsored by Chiesi Farmaceutici S.p.A.. The principal investigator is Lori Hartnett at Amryt Pharmaceuticals DAC. The trial plans to enroll 100 participants.